KRAS and non-small cell lung carcinoma: We found that the cell survival rate was from 32% to 85% on these 14 tested NSCLC cell lines upon LINC00857 knockdown with siRNAs, indicating that LINC00857 could affect cell proliferation regardless of the KRAS, EGFR, MET, LKB11, and TP53 mutation status and histological subtypes (Figure 1B).